Treatment of pulmonary arterial hypertension: The role of prostacyclin and prostaglandin analogs

Research output: Contribution to journalReview articlepeer-review

49 Scopus citations


Pulmonary arterial hypertension is a progressive, fatal disease characterized by elevated pulmonary arterial pressure ≥25 mm Hg and normal pulmonary capillary wedge pressure ≤15 mm Hg. Physiological features of pulmonary arterial hypertension are characterized clinically by the presence of pre-capillary pulmonary hypertension not caused by other conditions such as lung diseases or chronic thromboembolic pulmonary hypertension. There are several therapies currently available that have been shown to improve hemodynamics and improve outcomes in patients with pulmonary arterial hypertension. These therapies include synthetic prostacyclin and prostaglandin analogs, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors. Multiple prostacyclin and prostaglandin analog formulations are currently in use (both branded and generic), available for parenteral, inhaled, or oral administration. This review discusses the pharmacology, clinical effects, and routes of administration of prostacyclin and prostaglandin analogs, emphasizing the advantages and disadvantages of each from the clinical perspective.

Original languageEnglish (US)
Pages (from-to)818-827
Number of pages10
JournalRespiratory Medicine
Issue number6
StatePublished - Jun 2011


  • 6-Minute walk test distance
  • Epoprostenol
  • Iloprost
  • Right heart failure
  • Treprostinil

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Treatment of pulmonary arterial hypertension: The role of prostacyclin and prostaglandin analogs'. Together they form a unique fingerprint.

Cite this